Ask AI
ProCE Banner Activity

Thoughts on the Evolving Treatment Options for First-line Management of HER2-Positive mBC

Clinical Thought

Read this commentary with expert insights on emerging first-line treatment options for patients with HER2-positive metastatic breast cancer and important reinforcing takeaways from an educational program that may help enhance the management of these patients. 

Released: August 15, 2025

Share

Provided by

Provided by Clinical Care Options, LLC, in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Smart Patients

ProCE Banner

Disclosure

Primary Author

Shipra Gandhi, MD, MS: consultant/advisor/speaker: AstraZeneca, Hologic, Novartis, Roche.

Laura Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Precede, Seagen; researcher: AstraZeneca, Genentech, Gilead, Lilly, Merck; other (travel support): Lilly.